Trial shows cholesterol-lowering benefit of Vytorin

The results of the 9-year IMPROVE-IT trial show that Vytorin, a combination of the non-statin ezetimibe and simvastatin, may be useful in lowering LDL cholesterol and reducing the risk of CV events in high-risk patients with acute coronary syndromes.


	"The addition of ezetimibe to a statin resulted in a further reduction in cardiovascular events compared to statin therapy alone."

Other Coverage

• How safe is statin therapy?

• BMJ study: CV benefits of statin use far exceed risks

• 1 in 3 U.S. kids has borderline or high cholesterol